Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health Inc (HIMS, Financial), sold 9,868 shares of the company on October 7, 2024. The transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 195,988 shares of the company.
Hims & Hers Health Inc, a telehealth company, provides a modern approach to health and wellness. The company's platform connects consumers with licensed healthcare professionals, enabling them to access high-quality care for numerous conditions related to mental health, sexual health, dermatology, and primary care.
Over the past year, Oluyemi Okupe has sold a total of 264,187 shares and has not made any purchases of the company's stock. The insider transaction history for Hims & Hers Health Inc shows a trend with 1 insider buy and 83 insider sells over the past year.
On the date of the sale, shares of Hims & Hers Health Inc were trading at $19.96, giving the company a market cap of approximately $4.08 billion. The price-earnings ratio of the company stands at 235.75, significantly above both the industry median of 18.06 and the company's historical median.
According to the GF Value, the intrinsic value estimate for Hims & Hers Health Inc is $15.93 per share, making the stock modestly overvalued with a price-to-GF-Value ratio of 1.25.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor related to past returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
